Sulfamethazine

Quick links to important sections

Sulfamethazine

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sulfamethazine

What is Sulfamethazine?

Sulfamethazine is a synthetic antimicrobial agent belonging to the sulfonamide group, often referred to as "sulfa drugs." It is primarily utilized for its bacteriostatic properties, which allow it to inhibit the growth and reproduction of various microorganisms rather than destroying them outright.

Mechanism of Action

The compound operates as a competitive inhibitor of the enzyme dihydropteroate synthase. This enzyme is essential for the synthesis of dihydrofolic acid in many bacteria. By mimicking para-aminobenzoic acid (PABA), sulfamethazine prevents the bacteria from producing folic acid, which is a vital building block for nucleic acids and proteins. Because humans and other mammals obtain folic acid through their diet rather than synthesizing it internally, the drug specifically targets bacterial metabolic pathways.

Chemical Characteristics

Sulfamethazine is characterized by its white or yellowish-white crystalline powder form. It is poorly soluble in water but dissolves more readily in alkaline solutions or organic solvents. Chemically, it is identified by its molecular structure involving a sulfonamide group attached to a pyrimidine ring with methyl substituents, which influences its absorption and excretion rates within a biological system.

General Utility

Historically and in contemporary practice, sulfamethazine has been used to manage various bacterial infections, particularly those affecting the respiratory and gastrointestinal tracts. It is effective against a broad spectrum of both Gram-positive and Gram-negative organisms. Due to its specific pharmacokinetic profile, it is often selected for conditions where a sustained concentration of the antimicrobial agent is necessary to overcome the infection.

What side effects are possible with Sulfamethazine?

Possible Side Effects and Safety Information

Sulfamethazine, as a sulfonamide antimicrobial, is associated with documented adverse reactions spanning several major physiological systems as classified in official regulatory labels. The official safety profile details potential effects across system-organ classes including the Blood and Lymphatic System, Gastrointestinal Disorders, Nervous System, and Renal and Urinary Disorders.

Documented Adverse Reactions and Severity

Adverse effects are categorized by frequency, with reactions such as nausea, vomiting, and headache typically listed as Common or Very Common in regulatory documents for related sulfonamides. More serious, but generally less frequent, effects include severe Blood Dyscrasias (e.g., agranulocytosis, aplastic anemia) and severe Hypersensitivity Reactions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which have been associated with fatalities.

Population-Specific Safety Constraints

Specific safety constraints are outlined for vulnerable populations. The medicine is contraindicated in infants less than 2 months of age and in women pregnant at term due to the risk of kernicterus. Caution is also advised when the medicine is considered for patients with pre-existing severe renal or hepatic impairment. The labeling also notes that individuals with G6PD deficiency should be closely monitored for potential hemolytic anemia, an effect that is stated to be dose related.

Safety Restrictions and Timing

Regulatory documentation emphasizes the need to maintain adequate fluid intake to prevent crystalluria and stone formation. Furthermore, the risk for severe cutaneous reactions (SJS/TEN) is documented as being highest during the first month of treatment, defining a key time-related safety pattern.

Overdose and Emergency Response

Overdose and when to seek help — official regulatory information for Sulfamethazine

This section describes the officially documented information regarding Sulfamethazine (Sulfadimidine) overexposure, based strictly on government regulatory and toxicological sources.


Overdose Scope

Element Regulatory Statement/Documentation
Documented overdose presentations Acute manifestations include gastrointestinal effects (nausea, vomiting) and CNS effects (headache, dizziness, ataxia). Later signs may include fever and jaundice [NIH, FDA].
Physiological systems affected Primary systems affected include the Hematopoietic system, Renal system, Hepatic system, and the Central Nervous System [FDA Labeling].
Dose-related or exposure-related factors The onset of clinical signs like sore throat, pallor, or purpura are considered early indications of serious blood disorders resulting from high exposure.
Population-specific overdose notes Patients with impaired renal or hepatic function are identified as a caution group due to susceptibility to complications affecting primary elimination pathways [FDA Labeling].
Emergency-response statements A suspected overdose requires the individual to go to the emergency department of the closest hospital. Immediate reporting of any signs suggesting serious blood disorders is mandated [Government Instruction].
When immediate medical help is required Immediate medical help is required for any suspected overdose or upon the detection of signs indicating serious blood disorders, exactly as defined in the official labeling.

Overdose Classifications (High-Level)

Element Regulatory Statement/Documentation
Severity classification The profile includes life-threatening severe outcomes, particularly blood dyscrasias (aplastic anemia, agranulocytosis) and acute organ toxicity (toxic nephrosis, fulminant hepatic necrosis).
Regulatory basis Based on official prescribing information and toxicological reports documented by government health authorities.
Overdose-context constraints Management is restricted to symptomatic and supportive treatment; the official labeling does not specify a known antidote.

Connection to the overall overdose profile

Regulatory documents define the Sulfamethazine overdose profile by documenting the potential for progression from general systemic signs to severe, life-threatening organ toxicity and blood disorders. This documented risk of high severity necessitates the regulator-mandated instruction for individuals to seek immediate medical attention and hospital-based supportive care to manage potential complications.

Therapeutic Uses of Sulfamethazine

What Sulfamethazine Treats: Main Uses and Benefits

The primary therapeutic benefit of Sulfamethazine (Sulfadimidine) is centered on providing supportive treatment by controlling infections caused by susceptible bacterial and protozoal pathogens. This sulfonamide is commonly used in situations involving certain distressing symptoms.


Addressing Acute Systemic and Organ-Specific Symptom Patterns

Sulfamethazine is relevant for conditions where symptoms of systemic imbalance, such as fever, or symptoms related to inflammatory states in the respiratory tract are present. The medicine is relevant in clinical settings that involve acute or unstable symptom patterns associated with urogenital, gastrointestinal, or specific protozoal issues. This application may assist with easing symptoms that create noticeable physiological strain and support patients during episodes of heightened discomfort.

“It is applied across domains where additional symptomatic support is needed for infections affecting major organ systems.”

By contributing to easing the overall symptom load in these situations, this treatment helps patients cope more steadily with difficult episodes.


Quick Fact: Relevant for Symptoms of Inflammatory States

Quick Fact: Relevant for Symptoms of Inflammatory States Sulfamethazine is applied in contexts marked by increased discomfort or tension, such as those involving fever and localized inflammation. It is relevant in situations where short-term symptomatic assistance is needed to ease the symptomatic burden.

Regulatory References

  1. World Health Organization (WHO) Expert Committee on Food Additives (JECFA)

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Sulfamethazine (Sulfadimidine)

Sulfamethazine eligibility is defined by the strict rules governing the sulfonamide antimicrobial class, focusing on populations vulnerable to severe reactions and those with compromised drug metabolism. Use is generally permitted for adults who do not present any specific contraindications.

Contraindicated Populations
Infants less than 2 months of age (risk of kernicterus)
Nursing Mothers and Pregnant Patients in the third trimester
Patients with known Hypersensitivity to Sulfonamides
Patients with Porphyria or severe Hepatic or Renal Damage

For the older adult population, use is permitted but requires caution due to the higher likelihood of reduced renal and/or hepatic function. Use during the first two trimesters of pregnancy is considered not established. Restricted use applies to individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency or pre-existing Blood Dyscrasias, requiring critical appraisal before administration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Sulfamethazine (Sulfadimidine) focuses on combinations that are formally restricted, pharmacokinetic alterations via protein binding, and pharmacodynamic potentiation.

Formal Interaction Restrictions

The co-administration of Sulfamethazine is strictly contraindicated with substances that act as chemical antagonists, including Para-aminobenzoic acid (PABA) and its related esters such as procaine or tetracaine. Co-administration with methenamine is also restricted by official labeling.

Pharmacokinetic and Pharmacodynamic Interactions

Sulfamethazine may engage in a plasma protein binding displacement interaction. This action can lead to an increase in the plasma concentration of the free drug for co-administered substances, including oral anticoagulants and methotrexate. Conversely, drugs such as indomethacin and salicylates are documented to displace the sulfonamide, increasing the concentration of free Sulfamethazine in the body.

Furthermore, regulatory documents describe a risk of pharmacodynamic potentiation with several drug classes, potentially increasing the effects of sulfonylurea hypoglycemic agents, thiazide diuretics, and uricosuric agents. An enhanced toxicity risk is also noted when combined with ionophore anticoccidials.

Population-Specific Considerations

The official labeling specifies that patients with impaired hepatic or renal function may be at a greater risk of adverse effects due to decreased drug clearance and accumulation. Individuals with Glucose-6-Phosphate Dehydrogenase (G-6-PD) deficiency are also noted to be at risk for a specific drug-related reaction.

Mechanism of Action

Competitive Inhibition of Bacterial Metabolism

Sulfamethazine initiates its effect by acting as a competitive inhibitor of the essential bacterial enzyme, Dihydropteroate Synthase (DHPS). By structurally mimicking the key precursor Para-Aminobenzoic Acid (PABA), the drug occupies the enzyme's active site and physically blocks the bacteria from accessing the initial step required to synthesize folic acid.

Mechanistic Cascade and Bacteriostasis

This molecular blockade immediately arrests the necessary biochemical cascade, preventing the formation of Tetrahydrofolic Acid (THF), the vital cofactor needed for bacteria to synthesize purines and thymidine. The resulting inability to produce new DNA and RNA imposes a state of bacteriostasis, meaning the pathogen's growth and replication are halted. The mechanism’s selective toxicity ensures this effect is achieved without interfering with the host's own cellular metabolism, a consequence that supports pathogen elimination by host immunity.

Limitations Due to Mechanistic Constraint

The efficacy of this mechanism is constrained by its competitive nature; bacterial resistance often emerges through genetic mutations that alter the DHPS binding site or by increasing the endogenous production of PABA. These biological changes functionally weaken the inhibitory effect, allowing the resumption of bacterial nucleic acid synthesis and proliferation. The bacteriostatic effect requires functional host immunity for the effective clearance of the growth-arrested bacterial population.

Dosage and Administration Information

The usage of Sulfamethazine (Sulfadimidine) is governed by guidelines that specify the administration route, dose structure, and timing. The medicine is prepared in multiple forms, including oral tablets and suspensions, as well as parenteral solutions for injection.


Dosing schedules typically initiate treatment with a higher initial loading dose to quickly establish the required systemic concentrations. This is followed by a lower maintenance dose. For example, one regimen specifies an initial dose of 3.0 grams, followed by 1.0 to 1.5 grams in subsequent doses. The medicine is administered in divided daily doses, frequently scheduled every 6 hours. Other formulations, such as sustained-release types, may follow a less frequent pattern, such as once every 72 hours.


The established duration of use is short-term. Guidelines specify that the course of treatment should continue for 24 to 48 hours beyond the remission of disease signs, but typically not to exceed a total of 5 consecutive days in certain applications.


Proper administration conditions are defined in the label. Patients are instructed to maintain adequate fluid intake during the course of treatment to support systemic processes. Furthermore, liquid or powder forms must be correctly prepared (e.g., mixed into a fresh solution) before intake, and the drug must be used as the sole source of sulfonamide during the treatment period.

Recent Clinical Evidence

Research evidence / Overview of studies for Sulfamethazine

Evidence for Use in Susceptible Infections and Associated Symptoms

The research base for Sulfamethazine (Sulfadimidine) primarily consists of early clinical trials from earlier decades and modern studies of how the body handles the drug (pharmacokinetic studies). Research explored its role as an antimicrobial agent in conditions associated with acute or disruptive episodes where symptoms become more noticeable, particularly for infections caused by susceptible bacterial and protozoal pathogens. Studies monitored outcomes related to physical discomfort and systemic or functional imbalance, especially those linked to inflammatory or irritative states in the respiratory, urogenital, and gastrointestinal systems.

These early studies were used in studies examining microbiological clearance of targeted pathogens, which involves monitoring pathogen presence or absence. These initial studies contributed to the broader evidence landscape regarding the drug's historical research application as an antimicrobial.

However, the certainty remains low regarding the current application of single-entity Sulfamethazine. Comparative evidence is lacking against other antimicrobial treatments. The evidence derived from settings with varying symptom burdens provides context but does not determine whether an individual today will respond similarly.


Overview of Study Types and Strength of Evidence

The available research structure for single-entity Sulfamethazine relies on historical trials whose methodology predates current rigorous Randomized Controlled Trial (RCT) standards. The body of research for modern, single-entity use is characterized by limited availability of recent trials. The evidence level is often considered low, as the majority of current, high-quality RCTs in this area focus on combination therapies involving other related sulfonamides. Research highlights changes measured during short study periods, but the findings describe group patterns, not individual predictions.


What Remains Uncertain About Sulfamethazine Research

A key limitation is the lack of recent Randomized Controlled Trials (RCTs) focusing solely on the single-entity Sulfamethazine drug in humans. This means that comparative evidence against other antimicrobial treatments is lacking, and certainty remains low regarding its precise standing in current practice based on modern evidence standards.

Long-term effects are not well characterized by existing data. Research provides limited insight into long-term outcomes, and the durability of the anti-bacterial response over extended periods or the risk of later relapse are not well characterized. Research highlights what is known—the general historical use and pharmacokinetic profile—and what is still uncertain—the specific efficacy and safety profile compared to modern alternatives under current regulatory standards.

Key Studies & References

  1. Sulfadimidine - WHO | JECFA (Evaluation of veterinary drug residues)
  2. Sulfa drug | Description & Facts (Historical Context of Sulfonamides)

Frequently Asked Questions (FAQ)

Common questions about Sulfamethazine (FAQ)

Q: Are there known cross-sensitivities between Sulfamethazine and other sulfa drugs?

Official documents indicate that cross-sensitivity is a known concern within the sulfonamide drug class, to which Sulfamethazine belongs. Hypersensitivity to similar sulfonamide drugs is listed as a reason to restrict the use of this medicine. The review of any history of drug allergies is a necessary step prior to use.

Q: What happens if a dose of Sulfamethazine is missed?

Standard regulatory guidance for this class of medicine describes that the missed dose may be taken as soon as it is remembered. However, if the time for the next scheduled dose is approaching, the missed dose should be skipped, and the regular schedule resumed. Taking two doses at once to make up for a missed dose is generally noted to be avoided.

Q: Can Sulfamethazine affect kidney function?

Official safety information states that Sulfamethazine, like other sulfonamides, can potentially affect the kidneys. This may involve the formation of crystals in the urine, a condition known as crystalluria. Less frequently, serious effects on kidney function, such as nitrogen retention, have been associated with this drug class.

Q: Does Sulfamethazine interact with any herbal supplements?

Official regulatory guidance notes that herbal remedies and supplements are typically not tested to the same standard as prescription medicines. Therefore, there may be insufficient data to confirm the safety of combining Sulfamethazine with any specific herbal product or supplement.

Q: Can people with allergies to other drugs still use Sulfamethazine?

The official documents restrict the use of Sulfamethazine for patients who have a known hypersensitivity or allergic reaction specifically to sulfonamides or to chemically similar drugs. Allergies to medicines outside of the sulfonamide class do not typically present a direct contraindication. However, the disclosure of all known allergies remains a necessary step prior to receiving the medicine.

Q: Can people with liver problems take Sulfamethazine?

Use of Sulfamethazine is restricted for individuals with severe hepatic (liver) damage. Because the medicine is processed by the liver, impairment of this organ can lead to decreased drug clearance and accumulation in the body. The sulfonamide class has also been associated with rare cases of idiosyncratic liver injury.

Q: Is Sulfamethazine the same drug as Sulfadiazine?

No, Sulfamethazine and Sulfadiazine are two distinct medicines, although both belong to the same pharmacological class of sulfonamide antimicrobials. Sulfamethazine is also known by the international name Sulfadimidine, confirming its identity as a separate compound from Sulfadiazine.

Q: What is the difference between Sulfamethazine and Bactrim?

Sulfamethazine is a medicine that contains a single active ingredient. In contrast, Bactrim is a brand name for a combination drug that contains two active ingredients: the sulfonamide Sulfamethoxazole, and another antimicrobial agent called Trimethoprim.

Q: Can Sulfamethazine be used by children?

Regulatory guidance strictly prohibits the use of Sulfamethazine in infants younger than 2 months old due to safety concerns. For children 2 months of age and older, use is generally permitted, though professional guidance is required, as the necessary dosage is calculated specifically based on the child's body weight.

Q: Is Sulfamethazine suitable for older adults?

Use in older adults is generally permitted. However, official information advises caution, as older adults may be more likely to have age-related reductions in kidney or liver function. This change in organ function can potentially affect how Sulfamethazine is cleared from the body.

Q: Does Sulfamethazine have a long history of use?

Yes, authoritative reviews confirm that the sulfonamide class, including Sulfamethazine, has a long history in medicine. These compounds were among the first effective antibiotics to be used in clinical practice, dating back to the 1930s.

Q: What types of infections is Sulfamethazine prescribed for?

Sulfamethazine is an antimicrobial agent used against bacterial and protozoal pathogens that are susceptible to the drug. Historically, the sulfonamide class has been used to treat various infections, including urinary tract infections (UTIs).

Q: Do over-the-counter pain relievers interact with Sulfamethazine?

Official documents for related sulfonamide medicines indicate that interactions can occur with certain non-steroidal anti-inflammatory drugs (NSAIDs). For example, salicylates, which are found in some pain-relieving products, are noted to potentially interact with Sulfamethazine.

Q: Is Sulfamethazine considered a broad-spectrum antibiotic?

Authoritative reviews classify the sulfonamide class as having a wide range of antimicrobial activity. This means it has been shown to be active against many types of bacteria, including both gram-positive and gram-negative organisms.

Q: Is it normal to feel tired while taking Sulfamethazine?

Regulatory safety information for related medicines notes that unusual tiredness or weakness is a potential symptom that can be associated with certain serious side effects. These effects may include severe gastrointestinal issues or imbalances in the body's electrolytes.

Q: Is Sulfamethazine associated with any long-term effects?

Authoritative reviews on the sulfonamide class indicate that prolonged use has historically been associated with effects on systems including the liver, kidneys, and nervous system. However, for the single-entity Sulfamethazine drug, current data limitations mean that specific long-term outcomes are not well-characterized or fully established.

Q: Are there known effects of Sulfamethazine on blood sugar levels?

Official documents indicate that Sulfamethazine can interact with certain anti-diabetic medicines called sulfonylurea hypoglycemic agents, potentially increasing their effect. Additionally, reports of overdose within the sulfonamide class have been associated with a potential for diminished blood sugar levels.

How should Sulfamethazine be stored and disposed of?

How to Store and Dispose of Sulfamethazine

Sulfamethazine must be stored at a controlled room temperature, typically maintained between 15 C and 30 C (59 F and 86 F), according to regulatory documentation. It is essential to protect the medication from freezing and store it in its original container, ensuring the container is tightly closed when not in use. As with all medications, it must be kept out of the sight and reach of children.

For disposal, do not flush unused or expired Sulfamethazine down a toilet or pour it into a drain unless specifically instructed by official labeling. The recommended method is to use a medication take-back program or follow instructions from a governmental disposal guide to ensure proper and safe environmental handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Sulfamethazine found in:

A-Z Index: